Biovitrum AB moves to Karolinska Institutet

23-Feb-2005

Biovitrum AB is relocating its research and development department to the Karolinska Institutet campus in Solna, Sweden, a move that will enhance the possibility for both organisations to collaborate on medical research. The decision is also a key milestone in the development of Stockholm BioScience.

To start with, Biovitrum AB will be renting the research pavilions on Tomtebovägen from Akademiska Hus, who will construct a new NMR annex. The company will also be renting existing research premises from Karolinska Institutet in the Retzius Laboratory and the Scheele Laboratory. The move will take place in 2005.

Initially Biovitrum will be moving its Stockholm-based research and development operations and its management offices to Karolinska Institutet with the intention of eventually having all its research and development carried out at the university campus. Commercial Operations, the part of Biovitrum that deals with the process development and production of protein drugs and the marketing of pharmaceutical products, will be based on Strandbergsgatan in Stockholm.

Akademiska Hus is planning to erect three modern research labs of 8,000 sq.m. each in the Karolinska Science Park at the intersection of Solnavägen and Tomtebovägen. The architecture will be designed to represent renewal and modernity, juxtaposed with Karolinska Institutet's reputation of tradition. Biovitrum intends to move onto the Karolinska Science Park in 2008 once the buildings have been completed.

Over the past five years, Karolinska Institutet, the Royal Institute of Technology (KTH) and Stockholm University have been running a joint project, called Stockholm BioScience, in the North Station area to create an internationally attractive environment of multidisciplinary research centres and biotech companies. It is all part of new, vibrant city planning concept.

https://www.bionity.com/en/news/43647/biovitrum-ab-moves-to-karolinska-institutet.html